{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:53:03Z","timestamp":1784098383371,"version":"3.55.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple endocrine neoplasia type 1 (MEN1) syndrome is an autosomal dominant disorder caused by a germline pathogenic variant in the <jats:italic>MEN1<\/jats:italic> tumor suppressor gene. Patients with MEN1 have a high risk for primary hyperparathyroidism (PHPT) with a penetrance of nearly 100%, pituitary adenomas (PitAd) in 40% of patients, and neuroendocrine neoplasms (NEN) of the pancreas (40% of patients), duodenum, lung, and thymus. Increased MEN1-related mortality is mainly related to duodenal-pancreatic and thymic NEN. Management of PHPT differs from that of patients with sporadic disease, as the surgical approach in MEN1-related PHPT includes near-total or total parathyroidectomy because of multigland hyperplasia in most patients and the consequent high risk of recurrence. NEN management also differs from patients with sporadic disease due to multiple synchronous and metasynchronous neoplasms. In addition, the lifelong risk of developing NEN requires special considerations to avoid excessive surgeries and to minimize damage to the patient\u2019s function and well-being. This progress report will outline current insights into surveillance and management of the major clinical manifestation of MEN1 syndrome in children and adults with MEN1 diagnosis. In addition, we will discuss MEN1-like clinical presentation with negative <jats:italic>MEN1<\/jats:italic>-genetic workup and future clinical and research directions.<\/jats:p>","DOI":"10.1007\/s10689-025-00440-4","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T09:25:25Z","timestamp":1737192325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Progress report on multiple endocrine neoplasia type 1"],"prefix":"10.1007","volume":"24","author":[{"given":"Reut","family":"Halperin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Tirosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"440_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/science.276.5311.404","volume":"276","author":"SC Chandrasekharappa","year":"1997","unstructured":"Chandrasekharappa SC, Guru SC, Manickam P et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404\u2013407. https:\/\/doi.org\/10.1126\/science.276.5311.404","journal-title":"Science"},{"key":"440_CR2","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/jc.2012-1230","volume":"97","author":"RV Thakker","year":"2012","unstructured":"Thakker RV, Newey PJ, Walls GV et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990\u20133011. https:\/\/doi.org\/10.1210\/jc.2012-1230","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR3","doi-asserted-by":"publisher","unstructured":"Marini F, Giusti F, Iantomasi T, Brandi ML (2021) Parathyroid tumors: Molecular signatures. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms222011206","DOI":"10.3390\/ijms222011206"},{"key":"440_CR4","doi-asserted-by":"publisher","first-page":"1191040","DOI":"10.3389\/fendo.2023.1191040","volume":"14","author":"L Pierotti","year":"2023","unstructured":"Pierotti L, Pardi E, Dinoi E et al (2023) Cutaneous lesions and other non-endocrine manifestations of multiple endocrine neoplasia type 1 syndrome. Front Endocrinol (Lausanne) 14:1191040. https:\/\/doi.org\/10.3389\/fendo.2023.1191040","journal-title":"Front Endocrinol (Lausanne)"},{"key":"440_CR5","doi-asserted-by":"publisher","first-page":"1029041","DOI":"10.3389\/fendo.2022.1029041","volume":"13","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG (2022) Beyond the 3 ps: a critical appraisal of the non-endocrine manifestations of multiple endocrine neoplasia type 1. Front Endocrinol (Lausanne) 13:1029041. https:\/\/doi.org\/10.3389\/fendo.2022.1029041","journal-title":"Front Endocrinol (Lausanne)"},{"key":"440_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02288-w","author":"YX Zhao","year":"2023","unstructured":"Zhao YX, Wang O, Song A et al (2023) The risk of concurrent malignancies in patients with multiple endocrine neoplasia type 1: insights into clinical characteristics of those with multiple endocrine neoplasia type 1. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02288-w","journal-title":"J Endocrinol Invest"},{"key":"440_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ando.2023.09.003","volume":"85","author":"P Goudet","year":"2024","unstructured":"Goudet P, Cadiot G, Barlier A et al (2024) French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d\u2019\u00e9tude Des Tumeurs Endocrines\/Association Francophone De Chirurgie Endocrinienne\/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of M. Ann Endocrinol (Paris) 85:2\u201319","journal-title":"Ann Endocrinol (Paris)"},{"key":"440_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/qjmed\/89.9.653","volume":"89","author":"D Trump","year":"1996","unstructured":"Trump D, Farren B, Wooding C et al (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89:653\u2013669. https:\/\/doi.org\/10.1093\/qjmed\/89.9.653","journal-title":"QJM"},{"key":"440_CR9","doi-asserted-by":"publisher","unstructured":"van den Broek MFM, van Nesselrooij BPM, Pieterman CRC et al (2020) Clues for genetic anticipation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 105. https:\/\/doi.org\/10.1210\/clinem\/dgaa257","DOI":"10.1210\/clinem\/dgaa257"},{"key":"440_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00268-009-0290-1","volume":"34","author":"P Goudet","year":"2010","unstructured":"Goudet P, Murat A, Binquet C et al (2010) Risk factors and causes of death in MEN1 disease. A GTE (Groupe d\u2019Etude Des Tumeurs Endocrines) Cohort Study among 758 patients. World J Surg 34:249\u2013255. https:\/\/doi.org\/10.1007\/s00268-009-0290-1","journal-title":"World J Surg"},{"key":"440_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV et al (2023) MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615:913\u2013919. https:\/\/doi.org\/10.1038\/s41586-023-05755-9","journal-title":"Nature"},{"key":"440_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","volume":"38","author":"S Matkar","year":"2013","unstructured":"Matkar S, Thiel A, Hua X (2013) Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci 38:394\u2013402. https:\/\/doi.org\/10.1016\/j.tibs.2013.05.005","journal-title":"Trends Biochem Sci"},{"key":"440_CR13","doi-asserted-by":"publisher","first-page":"L15","DOI":"10.1530\/ERC-21-0226","volume":"28","author":"A Mandl","year":"2021","unstructured":"Mandl A, Welch JM, Kapoor G et al (2021) Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus. Endocr Relat Cancer 28:L15\u2013L19","journal-title":"Endocr Relat Cancer"},{"key":"440_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/humu.20605","volume":"29","author":"MC Lemos","year":"2008","unstructured":"Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29:22\u201332. https:\/\/doi.org\/10.1002\/humu.20605","journal-title":"Hum Mutat"},{"key":"440_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1349-7006.2008.01034.x","volume":"100","author":"T Tsukada","year":"2009","unstructured":"Tsukada T, Nagamura Y, Ohkura N (2009) MEN1 gene and its mutations: basic and clinical implications. Cancer Sci 100:209\u2013215. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.01034.x","journal-title":"Cancer Sci"},{"key":"440_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12020-018-1566-8","volume":"62","author":"F Marini","year":"2018","unstructured":"Marini F, Giusti F, Fossi C et al (2018) Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine 62:215\u2013233. https:\/\/doi.org\/10.1007\/s12020-018-1566-8","journal-title":"Endocrine"},{"key":"440_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1210\/jc.2018-01170","volume":"104","author":"P Romanet","year":"2019","unstructured":"Romanet P, Mohamed A, Giraud S et al (2019) UMD-MEN1 database: an overview of the 370 MEN1 variants Present in 1676 patients from the French Population. J Clin Endocrinol Metab 104:753\u2013764. https:\/\/doi.org\/10.1210\/jc.2018-01170","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR18","doi-asserted-by":"publisher","unstructured":"Blau JE, Simonds WF (2021) Familial Hyperparathyroidism. Front Endocrinol (Lausanne) 12:. https:\/\/doi.org\/10.3389\/fendo.2021.623667","DOI":"10.3389\/fendo.2021.623667"},{"key":"440_CR19","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1210\/jc.2014-1414","volume":"99","author":"R Eastell","year":"2014","unstructured":"Eastell R, Brandi ML, Costa AG et al (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3570\u20133579. https:\/\/doi.org\/10.1210\/jc.2014-1414","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR20","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1038\/nrdp.2016.33","volume":"2","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Cusano NE, Khan AA et al (2016) Primary hyperparathyroidism. Nat Rev Dis Primers 2:16033. https:\/\/doi.org\/10.1038\/nrdp.2016.33","journal-title":"Nat Rev Dis Primers"},{"key":"440_CR21","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1210\/jc.2014-2000","volume":"99","author":"R Udelsman","year":"2014","unstructured":"Udelsman R, \u00c5kerstr\u00f6m G, Biagini C et al (2014) The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3595\u20133606. https:\/\/doi.org\/10.1210\/jc.2014-2000","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR22","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1530\/EJE-19-0602","volume":"181","author":"S Vandeva","year":"2019","unstructured":"Vandeva S, Daly AF, Petrossians P et al (2019) Somatic and germline mutations in the pathogenesis of pituitary adenomas. Eur J Endocrinol 181:R235\u2013R254. https:\/\/doi.org\/10.1530\/EJE-19-0602","journal-title":"Eur J Endocrinol"},{"key":"440_CR23","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1093\/ejendo\/lvae120","volume":"191","author":"D Maiter","year":"2024","unstructured":"Maiter D, Chanson P, Constantinescu SM, Linglart A (2024) Diagnosis and management of pituitary adenomas in children and adolescents. Eur J Endocrinol 191:R55\u2013R69. https:\/\/doi.org\/10.1093\/ejendo\/lvae120","journal-title":"Eur J Endocrinol"},{"key":"440_CR24","doi-asserted-by":"publisher","unstructured":"Papadopoulou-Marketou N, Tsoli M, Chatzellis E et al (2024) Hereditary syndromes Associated with pancreatic and lung neuroendocrine tumors. Cancers (Basel) 16. https:\/\/doi.org\/10.3390\/cancers16112075","DOI":"10.3390\/cancers16112075"},{"key":"440_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000472255","volume":"105","author":"R Jia","year":"2017","unstructured":"Jia R, Sulentic P, Xu J-M, Grossman AB (2017) Thymic neuroendocrine neoplasms: Biological Behaviour and Therapy. Neuroendocrinology 105:105\u2013114. https:\/\/doi.org\/10.1159\/000472255","journal-title":"Neuroendocrinology"},{"key":"440_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1159\/000511791","volume":"111","author":"B Niederle","year":"2021","unstructured":"Niederle B, Selberherr A, Bartsch DK et al (2021) Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome - an International Consensus Statement. Neuroendocrinology 111:609\u2013630. https:\/\/doi.org\/10.1159\/000511791","journal-title":"Neuroendocrinology"},{"key":"440_CR27","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1210\/jc.2014-3659","volume":"100","author":"P Goudet","year":"2015","unstructured":"Goudet P, Dalac A, Le Bras M et al (2015) MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d\u2019\u00e9tude Des Tumeurs endocrines. J Clin Endocrinol Metab 100:1568\u20131577. https:\/\/doi.org\/10.1210\/jc.2014-3659","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1530\/EJE-16-1079","volume":"176","author":"A Tirosh","year":"2017","unstructured":"Tirosh A, Papadakis GZ, Millo C et al (2017) Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68 Ga-DOTATATE-Avid tumor volume measurements. Eur J Endocrinol 176:575\u2013582. https:\/\/doi.org\/10.1530\/EJE-16-1079","journal-title":"Eur J Endocrinol"},{"key":"440_CR29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad521","author":"D Bulzico","year":"2023","unstructured":"Bulzico D (2023) The search for a Reliable Biomarker in MEN1 Duodenopancreatic neuroendocrine tumors. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad521","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR30","doi-asserted-by":"publisher","unstructured":"Pieterman CRC, Grozinsky-Glasberg S, O\u2019Toole D et al (2024) Screening and surveillance practices for multiple endocrine neoplasia type 1-related neuroendocrine tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire study. J Neuroendocrinol e 13468. https:\/\/doi.org\/10.1111\/jne.13468","DOI":"10.1111\/jne.13468"},{"key":"440_CR31","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jbmr.4677","volume":"37","author":"Bilezikian","year":"2022","unstructured":"Bilezikian JP, Khan AA, Silverberg SJ et al (2022) Evaluation and management of primary hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Min Res 37:2293\u20132314. https:\/\/doi.org\/10.1002\/jbmr.4677","journal-title":"J Bone Min Res"},{"key":"440_CR32","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1359\/jbmr.090304","volume":"24","author":"C Eller-Vainicher","year":"2009","unstructured":"Eller-Vainicher C, Chiodini I, Battista C et al (2009) Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 24:1404\u20131410. https:\/\/doi.org\/10.1359\/jbmr.090304","journal-title":"J Bone Miner Res"},{"key":"440_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/SLA.0b013e31815efda5","volume":"247","author":"JA Norton","year":"2008","unstructured":"Norton JA, Venzon DJ, Berna MJ et al (2008) Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 247:501\u2013510. https:\/\/doi.org\/10.1097\/SLA.0b013e31815efda5","journal-title":"Ann Surg"},{"key":"440_CR34","doi-asserted-by":"publisher","first-page":"557050","DOI":"10.3389\/fendo.2020.557050","volume":"11","author":"A Song","year":"2020","unstructured":"Song A, Yang Y, Liu S et al (2020) Prevalence of Parathyroid Carcinoma and atypical parathyroid neoplasms in 153 patients with multiple endocrine neoplasia type 1: Case Series and Literature Review. Front Endocrinol (Lausanne) 11:557050. https:\/\/doi.org\/10.3389\/fendo.2020.557050","journal-title":"Front Endocrinol (Lausanne)"},{"key":"440_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10689-015-9840-x","volume":"15","author":"F Tonelli","year":"2016","unstructured":"Tonelli F, Biagini C, Giudici F et al (2016) Aortopulmonary window parathyroid gland causing primary hyperparathyroidism in men type 1 syndrome. Fam Cancer 15:133\u2013138. https:\/\/doi.org\/10.1007\/s10689-015-9840-x","journal-title":"Fam Cancer"},{"key":"440_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1245\/s10434-016-5467-x","volume":"23","author":"XM Keutgen","year":"2016","unstructured":"Keutgen XM, Nilubol N, Agarwal S et al (2016) Reoperative surgery in patients with multiple endocrine neoplasia type 1 Associated Primary Hyperparathyroidism. Ann Surg Oncol 23:701\u2013707. https:\/\/doi.org\/10.1245\/s10434-016-5467-x","journal-title":"Ann Surg Oncol"},{"key":"440_CR37","doi-asserted-by":"publisher","unstructured":"Talbot J-N, Zhang-Yin J, Kerrou K et al (2022) Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET\/CT. Illustrative cases and pitfalls. Q J of Nuclear Med Mol Imaging: Official Publication of Italian Association of Nuclear Med (AIMN) [and] Int Association of Radiopharmacology (IAR) [and] Sect of Soc of 66(130\u2013140). https:\/\/doi.org\/10.23736\/S1824-4785.22.03440-9","DOI":"10.23736\/S1824-4785.22.03440-9"},{"key":"440_CR38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/SLA.0b013e318208fed9","volume":"253","author":"R Udelsman","year":"2011","unstructured":"Udelsman R, Lin Z, Donovan P (2011) The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 253:585\u2013591. https:\/\/doi.org\/10.1097\/SLA.0b013e318208fed9","journal-title":"Ann Surg"},{"key":"440_CR39","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.surg.2014.08.006","volume":"156","author":"TC Lairmore","year":"2014","unstructured":"Lairmore TC, Govednik CM, Quinn CE et al (2014) A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 156:1325\u20131326. https:\/\/doi.org\/10.1016\/j.surg.2014.08.006","journal-title":"Surgery"},{"key":"440_CR40","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1210\/jc.2014-3255","volume":"100","author":"N Singh Ospina","year":"2015","unstructured":"Singh Ospina N, Thompson GB, Lee RA et al (2015) Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 100:E87\u201390. https:\/\/doi.org\/10.1210\/jc.2014-3255","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","volume":"52","author":"F Giusti","year":"2016","unstructured":"Giusti F, Cianferotti L, Gronchi G et al (2016) Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1). Endocrine 52:495\u2013506. https:\/\/doi.org\/10.1007\/s12020-015-0696-5","journal-title":"Endocrine"},{"key":"440_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1530\/EJE-12-0117","volume":"167","author":"M Filopanti","year":"2012","unstructured":"Filopanti M, Verga U, Ermetici F et al (2012) MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol 167:157\u2013164. https:\/\/doi.org\/10.1530\/EJE-12-0117","journal-title":"Eur J Endocrinol"},{"key":"440_CR43","doi-asserted-by":"publisher","unstructured":"Yavropoulou MP, Vlachou S, Tsoli M et al (2022) Management and Long-Term Follow-Up of hyperparathyroidism in multiple endocrine neoplasia type 1: single Center experience. J Clin Med 11. https:\/\/doi.org\/10.3390\/jcm11071967","DOI":"10.3390\/jcm11071967"},{"key":"440_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019\u2019Toole D, Costa F et al (2016) ENETS Consensus guidelines Update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172\u2013185. https:\/\/doi.org\/10.1159\/000443167","journal-title":"Neuroendocrinology"},{"key":"440_CR45","doi-asserted-by":"publisher","unstructured":"Murray A, Rodas Marquez SP, Krishnamurthy M et al (2024) Multifocal Insulinoma as the Unique presenting feature of multiple endocrine neoplasia type 1 in an adolescent. Horm Res Paediatr 1\u20139. https:\/\/doi.org\/10.1159\/000538211","DOI":"10.1159\/000538211"},{"key":"440_CR46","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s40618-023-02287-x","volume":"47","author":"C Smirne","year":"2024","unstructured":"Smirne C, Giacomini GM, Berton AM et al (2024) A novel likely pathogenetic variant p.(Cys235Arg) of the MEN1 gene in multiple endocrine neoplasia type 1 with multifocal glucagonomas. J Endocrinol Invest 47:1815\u20131825. https:\/\/doi.org\/10.1007\/s40618-023-02287-x","journal-title":"J Endocrinol Invest"},{"key":"440_CR47","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40618-022-01961-w","volume":"46","author":"S Massironi","year":"2022","unstructured":"Massironi S, Rossi RE, Laffusa A et al (2022) Sporadic and MEN1-related gastrinoma and zollinger\u2013Ellison syndrome: differences in clinical characteristics and survival outcomes. J Endocrinol Invest 46:957\u2013965. https:\/\/doi.org\/10.1007\/s40618-022-01961-w","journal-title":"J Endocrinol Invest"},{"key":"440_CR48","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3748\/wjg.v17.i10.1343","volume":"17","author":"M Imamura","year":"2011","unstructured":"Imamura M (2011) Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 17:1343. https:\/\/doi.org\/10.3748\/wjg.v17.i10.1343","journal-title":"World J Gastroenterol"},{"key":"440_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1148\/radiology.178.1.1984311","volume":"178","author":"JL Doppman","year":"1991","unstructured":"Doppman JL, Miller DL, Chang R et al (1991) Insulinomas: localization with selective intraarterial injection of calcium. Radiology 178:237\u2013241. https:\/\/doi.org\/10.1148\/radiology.178.1.1984311","journal-title":"Radiology"},{"key":"440_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/cen.14586","volume":"96","author":"R Shah","year":"2022","unstructured":"Shah R, Sehemby M, Garg R et al (2022) 68Ga-DOTATATE PET\/CT imaging in endogenous hyperinsulinemic hypoglycemia: a tertiary endocrine centre experience. Clin Endocrinol (Oxf) 96:190\u2013199. https:\/\/doi.org\/10.1111\/cen.14586","journal-title":"Clin Endocrinol (Oxf)"},{"key":"440_CR51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/01.sla.0000189549.51913.d8","volume":"242","author":"DK Bartsch","year":"2005","unstructured":"Bartsch DK, Fendrich V, Langer P et al (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242:757\u2013766. https:\/\/doi.org\/10.1097\/01.sla.0000189549.51913.d8","journal-title":"Ann Surg"},{"key":"440_CR52","doi-asserted-by":"publisher","first-page":"T243","DOI":"10.1530\/ERC-17-0285","volume":"24","author":"SM Sadowski","year":"2017","unstructured":"Sadowski SM, Cadiot G, Dansin E et al (2017) The future: surgical advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer 24:T243\u2013T260. https:\/\/doi.org\/10.1530\/ERC-17-0285","journal-title":"Endocr Relat Cancer"},{"key":"440_CR53","doi-asserted-by":"publisher","unstructured":"van Beek D-J, Pieterman CRC, Wessels FJ et al (2022) Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice. Front Endocrinol (Lausanne) 13. https:\/\/doi.org\/10.3389\/fendo.2022.926491","DOI":"10.3389\/fendo.2022.926491"},{"key":"440_CR54","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00268-012-1539-7","volume":"36","author":"MA Lewis","year":"2012","unstructured":"Lewis MA, Thompson GB, Young WF (2012) Preoperative Assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg 36:1375\u20131381. https:\/\/doi.org\/10.1007\/s00268-012-1539-7","journal-title":"World J Surg"},{"key":"440_CR55","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2967\/jnumed.111.101675","volume":"53","author":"AR Haug","year":"2012","unstructured":"Haug AR, Cindea-Drimus R, Auernhammer CJ et al (2012) The role of 68Ga-DOTATATE PET\/CT in suspected neuroendocrine tumors. J Nucl Med 53:1686\u20131692. https:\/\/doi.org\/10.2967\/jnumed.111.101675","journal-title":"J Nucl Med"},{"key":"440_CR56","doi-asserted-by":"publisher","unstructured":"Tirosh A, Papadakis GZ, Millo C et al (2017) Prognostic Utility of Total 68 Ga-DOTATATE-Avid Tumor volume in patients with neuroendocrine tumors. https:\/\/doi.org\/10.1053\/j.gastro.2017.11.008. Gastroenterology","DOI":"10.1053\/j.gastro.2017.11.008"},{"key":"440_CR57","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WFE, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500\u2013516. https:\/\/doi.org\/10.1148\/rg.352140164","journal-title":"Radiographics"},{"key":"440_CR58","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2967\/jnumed.115.163865","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Liu E, Blume JD et al (2016) Safety and efficacy of 68Ga-DOTATATE PET\/CT for diagnosis, staging, and Treatment Management of neuroendocrine tumors. J Nucl Med 57:708\u2013714. https:\/\/doi.org\/10.2967\/jnumed.115.163865","journal-title":"J Nucl Med"},{"key":"440_CR59","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-016-3319-3","volume":"43","author":"C Morgat","year":"2016","unstructured":"Morgat C, V\u00e9layoudom-C\u00e9phise F-L, Schwartz P et al (2016) Evaluation of 68Ga-DOTA-TOC PET\/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging 43:1258\u20131266. https:\/\/doi.org\/10.1007\/s00259-016-3319-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"440_CR60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jamcollsurg.2015.04.005","volume":"221","author":"SM Sadowski","year":"2015","unstructured":"Sadowski SM, Millo C, Cottle-Delisle C et al (2015) Results of 68Gallium-DOTATATE PET\/CT scanning in patients with multiple endocrine neoplasia type 1. J Am Coll Surg 221:509\u2013517. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2015.04.005","journal-title":"J Am Coll Surg"},{"key":"440_CR61","doi-asserted-by":"publisher","first-page":"e2056","DOI":"10.1210\/clinem\/dgab891","volume":"107","author":"C Mennetrey","year":"2022","unstructured":"Mennetrey C, Le Bras M, Bando-Delaunay A et al (2022) Value of somatostatin receptor PET\/CT in patients with MEN1 at various stages of their disease. J Clin Endocrinol Metab 107:e2056\u2013e2064. https:\/\/doi.org\/10.1210\/clinem\/dgab891","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR62","doi-asserted-by":"publisher","DOI":"10.1159\/000471879","author":"A Sundin","year":"2017","unstructured":"Sundin A, Arnold R, Baudin E et al (2017) ENETS Consensus guidelines for the standards of Care in Neuroendocrine tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. https:\/\/doi.org\/10.1159\/000471879","journal-title":"Neuroendocrinology"},{"key":"440_CR63","doi-asserted-by":"publisher","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E et al (2017) ENETS Consensus guidelines for the standards of Care in Neuroendocrine Neoplasia: peptide receptor radionuclide therapy with Radiolabeled Somatostatin Analogues. https:\/\/doi.org\/10.1159\/000475526. Neuroendocrinology","DOI":"10.1159\/000475526"},{"key":"440_CR64","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller H-H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656\u20134663. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol"},{"key":"440_CR65","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224\u2013233. https:\/\/doi.org\/10.1056\/NEJMoa1316158","journal-title":"N Engl J Med"},{"key":"440_CR66","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/cen.12411","volume":"80","author":"V Ramundo","year":"2014","unstructured":"Ramundo V, Del Prete M, Marotta V et al (2014) Impact of long-acting octreotide in patients with early\u2010stage MEN1\u2010related duodeno\u2010pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 80:850\u2013855. https:\/\/doi.org\/10.1111\/cen.12411","journal-title":"Clin Endocrinol (Oxf)"},{"key":"440_CR67","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1210\/clinem\/dgz007","volume":"105","author":"A Faggiano","year":"2020","unstructured":"Faggiano A, Modica R, Lo Calzo F et al (2020) Lanreotide Therapy vs active surveillance in MEN1-Related pancreatic neuroendocrine tumors\u2009<\u20092 centimeters. J Clin Endocrinol Metab 105:78\u201384. https:\/\/doi.org\/10.1210\/clinem\/dgz007","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR68","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E et al (2023) European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 35:e13318. https:\/\/doi.org\/10.1111\/jne.13318","journal-title":"J Neuroendocrinol"},{"key":"440_CR69","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12020-017-1234-4","volume":"58","author":"F Giusti","year":"2017","unstructured":"Giusti F, Cianferotti L, Boaretto F et al (2017) Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine 58:349\u2013359. https:\/\/doi.org\/10.1007\/s12020-017-1234-4","journal-title":"Endocrine"},{"key":"440_CR70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/EJE-10-0950","volume":"165","author":"P Goudet","year":"2011","unstructured":"Goudet P, Bonithon-Kopp C, Murat A et al (2011) Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d\u2019\u00e9tude Des Tumeurs endocrines. Eur J Endocrinol 165:97\u2013105. https:\/\/doi.org\/10.1530\/EJE-10-0950","journal-title":"Eur J Endocrinol"},{"key":"440_CR71","doi-asserted-by":"publisher","unstructured":"Syro LV, Scheithauer BW, Kovacs K et al (2012) Pituitary tumors in patients with MEN1 syndrome. Clinics (Sao Paulo) 67 suppl 1. 43\u201348. https:\/\/doi.org\/10.6061\/clinics\/2012(sup01)09","DOI":"10.6061\/clinics\/2012(sup01)09"},{"key":"440_CR72","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","volume":"87","author":"B Verg\u00e8s","year":"2002","unstructured":"Verg\u00e8s B, Boureille F, Goudet P et al (2002) Pituitary Disease in MEN Type 1 (MEN1): data from the France-Belgium MEN1 Multicenter Study. J Clin Endocrinol Metab 87:457\u2013465. https:\/\/doi.org\/10.1210\/jcem.87.2.8145","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR73","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cen.13796","volume":"89","author":"A Makri","year":"2018","unstructured":"Makri A, Bonella MB, Keil MF et al (2018) Children with MEN1 gene mutations may present first (and at a young age) with Cushing disease. Clin Endocrinol (Oxf) 89:437\u2013443. https:\/\/doi.org\/10.1111\/cen.13796","journal-title":"Clin Endocrinol (Oxf)"},{"key":"440_CR74","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0002-9343(80)80013-1","volume":"69","author":"NR Farid","year":"1980","unstructured":"Farid NR, Buehler S, Russell NA et al (1980) Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Am J Med 69:874\u2013880. https:\/\/doi.org\/10.1016\/S0002-9343(80)80013-1","journal-title":"Am J Med"},{"key":"440_CR75","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1210\/jcem.81.7.8675591","volume":"81","author":"JR Burgess","year":"1996","unstructured":"Burgess JR, Shepherd JJ, Parameswaran V et al (1996) Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 81:2642\u20132646. https:\/\/doi.org\/10.1210\/jcem.81.7.8675591","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR76","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12916-016-0708-1","volume":"14","author":"JM de Laat","year":"2016","unstructured":"de Laat JM, van der Luijt RB, Pieterman CRC et al (2016) MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med 14:182. https:\/\/doi.org\/10.1186\/s12916-016-0708-1","journal-title":"BMC Med"},{"key":"440_CR77","doi-asserted-by":"publisher","first-page":"15558","DOI":"10.1073\/pnas.0603877103","volume":"103","author":"NS Pellegata","year":"2006","unstructured":"Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103:15558\u201315563. https:\/\/doi.org\/10.1073\/pnas.0603877103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"440_CR78","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12020-016-0941-6","volume":"55","author":"S Borsari","year":"2017","unstructured":"Borsari S, Pardi E, Pellegata NS et al (2017) Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine 55:386\u2013397. https:\/\/doi.org\/10.1007\/s12020-016-0941-6","journal-title":"Endocrine"},{"key":"440_CR79","doi-asserted-by":"publisher","unstructured":"Halperin R, Arnon L, Nasirov S et al (2023) Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer 30. https:\/\/doi.org\/10.1530\/ERC-22-0174","DOI":"10.1530\/ERC-22-0174"},{"key":"440_CR80","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajhg.2016.08.018","volume":"99","author":"B Guan","year":"2016","unstructured":"Guan B, Welch JM, Sapp JC et al (2016) GCM2-Activating mutations in familial isolated hyperparathyroidism. Am J Hum Genet 99:1034\u20131044. https:\/\/doi.org\/10.1016\/j.ajhg.2016.08.018","journal-title":"Am J Hum Genet"},{"key":"440_CR81","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ecl.2018.07.002","volume":"47","author":"K Peissig","year":"2018","unstructured":"Peissig K, Condie BG, Manley NR (2018) Embryology of the parathyroid glands. Endocrinol Metab Clin North Am 47:733\u2013742. https:\/\/doi.org\/10.1016\/j.ecl.2018.07.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"440_CR82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.surg.2017.04.027","volume":"163","author":"M El Lakis","year":"2018","unstructured":"El Lakis M, Nockel P, Guan B et al (2018) Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. Surgery 163:31\u201334. https:\/\/doi.org\/10.1016\/j.surg.2017.04.027","journal-title":"Surgery"},{"key":"440_CR83","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1210\/js.2017-00043","volume":"1","author":"B Guan","year":"2017","unstructured":"Guan B, Welch JM, Vemulapalli M et al (2017) Ethnicity of patients with germline GCM2-Activating variants and primary hyperparathyroidism. J Endocr Soc 1:488\u2013499. https:\/\/doi.org\/10.1210\/js.2017-00043","journal-title":"J Endocr Soc"},{"key":"440_CR84","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/EJE-21-0433","volume":"186","author":"L Canaff","year":"2022","unstructured":"Canaff L, Guarnieri V, Kim Y et al (2022) Novel glial cells Missing-2 (GCM2) variants in parathyroid disorders. Eur J Endocrinol 186:351\u2013366. https:\/\/doi.org\/10.1530\/EJE-21-0433","journal-title":"Eur J Endocrinol"},{"key":"440_CR85","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12020-023-03560-y","volume":"83","author":"Q Asla","year":"2024","unstructured":"Asla Q, Sard\u00e0 H, Segu\u00ed N et al (2024) Clinical and outcome comparison of genetically positive vs. negative patients in a large cohort of suspected familial hypocalciuric hypercalcemia. Endocrine 83:747\u2013756. https:\/\/doi.org\/10.1007\/s12020-023-03560-y","journal-title":"Endocrine"},{"key":"440_CR86","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1210\/jc.2015-3442","volume":"101","author":"R Vargas-Poussou","year":"2016","unstructured":"Vargas-Poussou R, Mansour-Hendili L, Baron S et al (2016) Familial hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism: similarities and differences. J Clin Endocrinol Metab 101:2185\u20132195. https:\/\/doi.org\/10.1210\/jc.2015-3442","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR87","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ng1048","volume":"32","author":"JD Carpten","year":"2002","unstructured":"Carpten JD, Robbins CM, Villablanca A et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676\u2013680. https:\/\/doi.org\/10.1038\/ng1048","journal-title":"Nat Genet"},{"key":"440_CR88","doi-asserted-by":"publisher","unstructured":"Gheorghe A-M, Sima O-C, Florescu AF et al (2024) Insights into Hyperparathyroidism-Jaw Tumour Syndrome: from endocrine acumen to the spectrum of CDC73 gene and Parafibromin-Deficient Tumours. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25042301","DOI":"10.3390\/ijms25042301"},{"key":"440_CR89","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1210\/clinem\/dgad368","volume":"108","author":"R Tora","year":"2023","unstructured":"Tora R, Welch J, Sun J et al (2023) Phenotypic profiling and molecular mechanisms in hyperparathyroidism-jaw Tumor Syndrome. J Clin Endocrinol Metab 108:3165\u20133177. https:\/\/doi.org\/10.1210\/clinem\/dgad368","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02366-7","author":"F Cetani","year":"2024","unstructured":"Cetani F, Dinoi E, Pierotti L, Pardi E (2024) Familial states of primary hyperparathyroidism: an update. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-024-02366-7","journal-title":"J Endocrinol Invest"},{"key":"440_CR91","doi-asserted-by":"publisher","unstructured":"Binter T, Baumgartner-Parzer S, Schernthaner-Reiter MH et al (2024) Does genotype-specific phenotype in patients with multiple endocrine neoplasia type 2 Occur as current guidelines predict? Cancers (Basel) 16. https:\/\/doi.org\/10.3390\/cancers16030494","DOI":"10.3390\/cancers16030494"},{"key":"440_CR92","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1530\/EC-20-0163","volume":"9","author":"LV Larsen","year":"2020","unstructured":"Larsen LV, Mirebeau-Prunier D, Imai T et al (2020) Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocr Connect 9:489\u2013497. https:\/\/doi.org\/10.1530\/EC-20-0163","journal-title":"Endocr Connect"},{"key":"440_CR93","doi-asserted-by":"publisher","unstructured":"Bilbao Garay I, Daly AF, Ega\u00f1a Zunzunegi N, Beckers A (2020) Pituitary Disease in AIP mutation-positive familial isolated pituitary adenoma (FIPA): a Kindred-based overview. J Clin Med 9. https:\/\/doi.org\/10.3390\/jcm9062003","DOI":"10.3390\/jcm9062003"},{"key":"440_CR94","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","volume":"371","author":"G Trivellin","year":"2014","unstructured":"Trivellin G, Daly AF, Faucz FR et al (2014) Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 371:2363\u20132374. https:\/\/doi.org\/10.1056\/NEJMoa1408028","journal-title":"N Engl J Med"},{"key":"440_CR95","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ajhg.2022.02.002","volume":"109","author":"M Franke","year":"2022","unstructured":"Franke M, Daly AF, Palmeira L et al (2022) Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism. Am J Hum Genet 109:553\u2013570. https:\/\/doi.org\/10.1016\/j.ajhg.2022.02.002","journal-title":"Am J Hum Genet"},{"key":"440_CR96","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1210\/clinem\/dgaa501","volume":"106","author":"ME Lee","year":"2021","unstructured":"Lee ME, Ortega-Sustache YM, Agarwal SK et al (2021) Patients with MEN1 are at an increased risk for venous thromboembolism. J Clin Endocrinol Metab 106:e460\u2013e468. https:\/\/doi.org\/10.1210\/clinem\/dgaa501","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR97","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1210\/jc.2016-3690","volume":"102","author":"RS Van Leeuwaarde","year":"2017","unstructured":"Van Leeuwaarde RS, Dreijerink KM, Ausems MG et al (2017) MEN1-dependent breast cancer: indication for early screening? Results from the Dutch MEN1 study group. J Clin Endocrinol Metab 102:2083\u20132090. https:\/\/doi.org\/10.1210\/jc.2016-3690","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR98","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02288-w","author":"Yxing Zhao","year":"2023","unstructured":"Zhao Yxing, Wang O, Song A et al (2023) The risk of concurrent malignancies in patients with multiple endocrine neoplasia type 1: insights into clinical characteristics of those with multiple endocrine neoplasia type 1. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02288-w","journal-title":"J Endocrinol Invest"},{"key":"440_CR99","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/clinem\/dgad315","volume":"108","author":"JF Fahrmann","year":"2023","unstructured":"Fahrmann JF, Wasylishen AR, Pieterman CRC et al (2023) Blood-based Proteomic Signatures Associated with MEN1-related duodenopancreatic neuroendocrine tumor progression. J Clin Endocrinol Metab 108:3260\u20133271. https:\/\/doi.org\/10.1210\/clinem\/dgad315","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR100","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41422-022-00613-1","volume":"32","author":"Y Ma","year":"2022","unstructured":"Ma Y, Zhu Q, Wang X et al (2022) Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells. Cell Res 32:596\u2013599. https:\/\/doi.org\/10.1038\/s41422-022-00613-1","journal-title":"Cell Res"},{"key":"440_CR101","unstructured":"clinicaltrials.gov Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial (LUMEN1). https:\/\/clinicaltrials.gov\/study\/NCT05605587?cond=MEN1%26rank=1. Accessed 12 Jul 2024"},{"key":"440_CR102","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1038\/s41467-023-39990-5","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen X, Li Y, Zhu F et al (2023) Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma. Nat Commun 14:4259. https:\/\/doi.org\/10.1038\/s41467-023-39990-5","journal-title":"Nat Commun"},{"key":"440_CR103","doi-asserted-by":"publisher","first-page":"15519","DOI":"10.1021\/acs.jmedchem.1c00872","volume":"64","author":"H Lei","year":"2021","unstructured":"Lei H, Zhang S-Q, Fan S et al (2021) Recent progress of small Molecule Menin-MLL Interaction inhibitors as therapeutic agents for Acute Leukemia. J Med Chem 64:15519\u201315533. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00872","journal-title":"J Med Chem"},{"key":"440_CR104","doi-asserted-by":"publisher","first-page":"202","DOI":"10.14348\/molcells.2021.0206","volume":"45","author":"T Kim","year":"2022","unstructured":"Kim T, Jeong K, Kim E et al (2022) Menin enhances androgen receptor-independent Proliferation and Migration of prostate Cancer cells. Mol Cells 45:202\u2013215. https:\/\/doi.org\/10.14348\/molcells.2021.0206","journal-title":"Mol Cells"},{"key":"440_CR105","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/1541-7786.MCR-20-0679","volume":"19","author":"JA Jim\u00e9nez","year":"2021","unstructured":"Jim\u00e9nez JA, Apfelbaum AA, Hawkins AG et al (2021) EWS-FLI1 and Menin Converge to regulate ATF4 activity in Ewing Sarcoma. Mol Cancer Res 19:1182\u20131195. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0679","journal-title":"Mol Cancer Res"},{"key":"440_CR106","doi-asserted-by":"publisher","first-page":"1427821","DOI":"10.3389\/fendo.2024.1427821","volume":"15","author":"N Vald\u00e9s","year":"2024","unstructured":"Vald\u00e9s N, Romero A, Diego E et al (2024) Long term outcomes of pituitary adenomas in multiple endocrine neoplasia type 1: a nationwide study. Front Endocrinol (Lausanne) 15:1427821. https:\/\/doi.org\/10.3389\/fendo.2024.1427821","journal-title":"Front Endocrinol (Lausanne)"},{"key":"440_CR107","doi-asserted-by":"publisher","unstructured":"Clemente-Gutierrez U, Pieterman CRC, Lui MS et al (2024) Beyond the three P\u2019s: adrenal involvement in MEN1. Endocr Relat Cancer 31. https:\/\/doi.org\/10.1530\/ERC-23-0162","DOI":"10.1530\/ERC-23-0162"},{"key":"440_CR108","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cen.14430","volume":"95","author":"J Manoharan","year":"2021","unstructured":"Manoharan J, Anlauf M, Albers MB et al (2021) Gastric enterochromaffin-like cell changes in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 95:439\u2013446. https:\/\/doi.org\/10.1111\/cen.14430","journal-title":"Clin Endocrinol (Oxf)"},{"key":"440_CR109","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1210\/jc.2007-2279","volume":"93","author":"MJ Berna","year":"2008","unstructured":"Berna MJ, Annibale B, Marignani M et al (2008) A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 93:1582\u20131591. https:\/\/doi.org\/10.1210\/jc.2007-2279","journal-title":"J Clin Endocrinol Metab"},{"key":"440_CR110","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1530\/ERC-13-0482","volume":"21","author":"CRC Pieterman","year":"2014","unstructured":"Pieterman CRC, Conemans EB, Dreijerink KMA et al (2014) Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Endocr Relat Cancer 21:R121\u2013R142. https:\/\/doi.org\/10.1530\/ERC-13-0482","journal-title":"Endocr Relat Cancer"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00440-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00440-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00440-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T18:41:33Z","timestamp":1745260893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00440-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00440-4","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}